New combo therapy targets deadly brain cancer recurrence
NCT ID NCT03961971
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether combining a precise form of radiation (stereotactic radiosurgery) with two immunotherapy drugs (MBG453 and spartalizumab) is safe for people whose glioblastoma has come back. The study includes 16 adults with recurrent GBM. The main goal is to identify serious side effects, not to cure the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Stanford University
Stanford, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a parasite drug fight childhood brain tumors?
- Can a special MRI reveal hidden brain tumors and guide a stronger radiation strike?
- Can mapping the Blood-Brain barrier in brain tumors unlock new clues?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Brain cancer vaccine targets survivin protein to boost immune attack
- AI reads brain scans to predict tumor survival before surgery